Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (261.6), the stock would be worth ¥0.06 (99% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 29 327.7 | ¥6.24 |
0%
|
| 3-Year Average | 261.6 | ¥0.06 |
-99%
|
| 5-Year Average | 18.9 | ¥0 |
-100%
|
| Industry Average | 36.8 | ¥0.01 |
-100%
|
| Country Average | 28.9 | ¥0.01 |
-100%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Guangdong VTR Bio-Tech Co Ltd
SZSE:300381
|
3.1B CNY | 29 327.7 | 471.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 19.3 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 13.9 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 14.5 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 21.4 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 14.7 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 41.8 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 13.1 | 30.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Guangdong VTR Bio-Tech Co Ltd
Glance View
Guangdong VTR Bio-Tech Co., Ltd. is engaged in the research & development, production, sales and service of biological pharmacy, bio-enzyme preparation, microbe preparation, functional additives and green bio-manufacturing engineering. The company is headquartered in Zhuhai, Guangdong and currently employs 2,807 full-time employees. The company went IPO on 2014-01-28. The firm principally engages in the manufacture and distribution of feedstuff additives, additive pre-mixed feedstuffs, veterinary powders and granules. The Company’s products include enzyme preparations for feedstuffs, including composite enzyme for feedstuffs, phytase for feedstuffs and xylanase for feedstuffs, among others; bio-energy enzyme preparations; spinning enzyme products; food enzyme products; paper making enzyme products; other feedstuff additives, including antioxidants, acidifiers, attractants and fructo oligo saccharides feedstuff additives, as well as veterinary Chinese medicines.
